Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Recludix Pharma, Inc.

Recludix Pharma to Participate in Two Investor Conferences in December
From Recludix Pharma, Inc.
Via GlobeNewswire
Recludix Pharma to Present Data Demonstrating its Oral STAT3 Inhibitor has Differentiated Efficacy and Safety as Compared to JAK/TYK2 Inhibition in In Vivo Models of Inflammatory Arthritis
From Recludix Pharma, Inc.
Via GlobeNewswire
Fierce Biotech Names Recludix Pharma a “Fierce 15” Biotech Company of 2024
From Recludix Pharma, Inc.
Via GlobeNewswire
Recludix Pharma Presents Data Demonstrating Oral STAT3 Inhibitors Drive Differentiated Efficacy and Safety in Preclinical Models of Th17 Mediated Skin Inflammation in Oral Plenary Session at SID Annual Meeting
From Recludix Pharma, Inc.
Via GlobeNewswire
Recludix Pharma Announces the Appointment of Dr. Ajay Nirula, Accomplished Pharma Executive and Immunology Expert, as Executive Vice President and Head of Research and Development, and Strengthens Scientific Advisory Board with the Addition of Dr. Adrian
From Recludix Pharma, Inc.
Via GlobeNewswire
Recludix Pharma to Participate in Two Investor Conferences in March
From Recludix Pharma, Inc.
Via GlobeNewswire
Recludix Pharma to Present at Two Investor Conferences in February
From Recludix Pharma, Inc.
Via GlobeNewswire
Recludix Pharma to Present at Two Investor Conferences in November
From Recludix Pharma, Inc.
Via GlobeNewswire
Recludix Pharma Presents Preclinical Data Demonstrating Strong Efficacy and Favorable Safety Profile of REX-7117 Versus TYK2 and JAK Inhibitors at the Dermatology Drug Development Summit
From Recludix Pharma, Inc.
Via GlobeNewswire
Recludix Pharma Presents Preclinical Data from its STAT3 Inhibitor Program at the International Conference of the Inflammation Research Association (IRA)
From Recludix Pharma, Inc.
Via GlobeNewswire
Recludix Pharma to Participate in Multiple Investor Conferences in September
From Recludix Pharma, Inc.
Via GlobeNewswire
Recludix Pharma Enters into a Strategic Collaboration with Sanofi to Advance Novel Oral STAT6 Inhibitor in Multiple Immunological and Inflammatory Indications
From Recludix Pharma, Inc.
Via GlobeNewswire
Tickers SNY
Recludix Pharma to Present at the Oppenheimer 33rd Annual Healthcare Conference
From Recludix Pharma, Inc.
Via GlobeNewswire
Recludix Pharma to Present at the Guggenheim Healthcare Talks Oncology Conference
From Recludix Pharma, Inc.
Via GlobeNewswire
Recludix Pharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Recludix Pharma, Inc.
Via GlobeNewswire
Recludix Pharma Announces the Appointment of Accomplished Immunologist and Pharmacologist Paul A. Smith, Ph.D., as Senior Vice President of Biology
From Recludix Pharma, Inc.
Via GlobeNewswire
Recludix Pharma Announces the Appointment of Senior Executive Matthew S. Caldemeyer as Chief Business Officer
From Recludix Pharma, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.